Neuroendocrine tumours: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

15 of 15+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R43

  Development of a PET Imaging Platform to De-Risk AAV Gene Therapy Clinical Trials

  Neocell Technologies Inc· Fair Lawn, United States· US$306,395 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Novel Non-Mutagenic Ribosome Biogenesis Inhibitors for the Treatment of Small Cell Lung Cancer

  Palade Therapeutics Inc.· Austin, United States· US$404,087 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics

  Yale University· New Haven, United States· US$532,637 awarded in fiscal year 2026· until Aug 2031

• NIH NIBIB · U24

  Medical Imaging and Data Resource Center (MIDRC) – Expansion to Theranostics

  University of Chicago· Chicago, United States· US$1,014,676 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €268,569· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €4,574,378· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norway· EU contribution €4,773,849· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxembourg· EU contribution €14,837,694· until Dec 2029· 13 countries

10 of 194 running projects, newest first. Listed amounts together: US$116.1m + €37.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  NCT04924075· Merck Sharp & Dohme LLC· Source

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Source

• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

  NCT04074135· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 186
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 202
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Capture and Isolation of Circulating Melanoma Cells Using Photoacoustic Flowmetry.

  Methods Mol Biol, Jan 2027

• Imaging and Analysis of Melanoma-Secreted Extracellular Vesicles in Tumor-Draining Lymph Nodes.

  Methods Mol Biol, Jan 2027

• A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.

  Methods Mol Biol, Jan 2027

• A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.

  Methods Mol Biol, Jan 2027

• Evaluating Melanoma Cell Migration/Invasion in Transwell Assays by Flow Cytometry.

  Methods Mol Biol, Jan 2027

• Anti-tumour activity of canine activated T-cells and cytokine-induced killer cells against canine malignant melanoma in vitro.

  Vet J, Jul 2026

• Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.

  Diagn Cytopathol, Jul 2026

• LNP-Delivered CAR-mRNA Enables in Vivo CAR-Macrophage Production for TYRP1-Targeted Therapy of Choroidal Melanoma.

  Curr Eye Res, Apr 2026

• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

  Eur J Surg Oncol, Jan 2026

• PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

  Nat Commun, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.